Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.72 |
| ▸ | MAOB | P27338 | 4/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | SDHA | P31040 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CALML3 | P27482 | 1/20 | 0.72 |
| ▸ | F10 | P00742 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12950996 | 1.00 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13034192 | 1.00 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701350 | 0.92 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701349 | 0.92 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3328441 | 0.91 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3328443 | 0.91 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3753257 | 0.90 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL701373 | 0.90 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2088204 | 0.90 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3206976 | 0.90 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | MELINTA SUBSIDIARY CORP. | 2015-06-11 | — | — | US | disclosed |
| EP-1660465-B1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | MELINTA THERAPEUTICS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8895741-B2 | Process for the synthesis of biaryl oxazolidinones | MELINTA THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8796465-B2 | Process for the syntheses of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | MELINTA SUBSIDIARY CORP. | 2013-03-14 | — | — | US | disclosed |
| US-20090306389-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2009-12-10 | — | — | US | disclosed |
| US-7002020-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-6562844-B2 | Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-6531470-B1 | Antimicrobial compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-11 | — | — | US | disclosed |
| US-20020183371-A1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | GORDEEV MIKHAIL F (US) | 2002-12-05 | — | — | US | disclosed |
| US-20020169191-A1 | Oxazolidinone compounds and methods of preparation and use thereof | PHARMACIA & UPJOHN COMPANY (US) | 2002-11-14 | — | — | US | disclosed |
| US-6441005-B1 | BACTERICIDES, ANTIBIOTICS AND MICROBIOCIDES | PHARMACIA & UPJOHN COMPANY | 2002-08-27 | — | — | US | disclosed |
| EP-1200416-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIINFECTIVES | Pharmacia & Upjohn Company (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6239152-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2001009107-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIINFECTIVES | PHARMACIA & UPJOHN COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-1049682-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | Versicor, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037630-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | VERSICOR, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | PCNA, PGC, SBDS | MAOA 1272/4885MAOB 1133/4885PTGS1 203/4885 |
| US-20090306389-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | OXA1L, NQO1, NQO2 | MAOA 590/4885MAOB 391/4885PTGS1 1820/4885 |
| US-20020183371-A1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PAICS, CDK4, OXA1L | MAOA 1267/4885MAOB 1298/4885PTGS1 4238/4885 |
| US-20020169191-A1 | Oxazolidinone compounds and methods of preparation and use thereof | OXA1L, PAM, DPM1 | MAOA 968/4885MAOB 852/4885PTGS1 2690/4885 |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CUTA, CYP19A1, KAT2A | MAOA 379/4885MAOB 219/4885PTGS1 2113/4885 |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | PROKR1, VIP, SI | MAOA 1794/4885MAOB 1380/4885PTGS1 49/4885 |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | PROKR1, SI, IL33 | MAOA 1726/4885MAOB 1344/4885PTGS1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.